低分子肝素联合多西他赛二线治疗驱动基因阴性晚期非小细胞肺癌的临床观察  

Therapeutic effect of low molecular weight heparin combined with Docetaxel for second-line treatment of advanced non-small cell lung cancer with driver gene-negative

作　　者：毛延涛 姜茂竹 MAO Yantao;JIANG Maozhu(Department of Oncology,Yantai Shan Hospital,Shandong Province,Yantai 264000,China;Department of Radiotherapy,Yantai Shan Hospital,Shandong Province,Yantai 264000,China)

机构地区：[1]山东省烟台市烟台山医院肿瘤内二科,山东烟台264000 [2]山东省烟台市烟台山医院放疗二科,山东烟台264000

出　　处：《中国当代医药》2024年第12期91-94,99,共5页China Modern Medicine

基　　金：山东省医药卫生科技发展计划项目(2018WS034)。

摘　　要：目的探讨低分子肝素(LMWH)联合多西他赛二线治疗驱动基因阴性晚期非小细胞肺癌(NSCLC)的临床观察。方法选取2017年10月至2020年9月烟台市烟台山医院收治的符合标准的100例晚期NSCLC患者作为研究对象,按照随机数字表法分为研究组和对照组,每组50例。研究组采用多西他赛化疗联合LMWH的方法。对照组采用多西他赛单药化疗的方法,直到疾病进展或不良反应不可耐受。比较两组治疗效果、凝血功能变化及不良反应。结果治疗2周期后疗效评价,两组患者的客观缓解率比较,差异无统计学意义(P>0.05)。治疗后,研究组疾病控制率高于对照组,差异有统计学意义(P<0.05)。治疗后,研究组D-二聚体、纤维蛋白原(FIB)含量均低于对照组,差异有统计学意义(P<0.05),研究组深静脉血栓发生率低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应比较,差异无统计学意义(P>0.05)。结论LMWH联合多西他赛二线治疗驱动基因阴性的晚期NSCLC疗效较好,可以提高疾病控制率,改善凝血功能,减少静脉血栓发生。Objective To investigate the clinical observation of low molecular weight heparin(LMWH)combined with Docetaxel in second-line treatment of advanced non-small cell lung cancer(NSCLC)with negative driver genes.Methods A total of 100 patients with advanced NSCLC who met the criteria and were admitted to Yantai Shan Hospital from October 2017 to September 2020 were selected as study objects,and they were divided into study group and control group according to the random number table method,with 50 cases in each group.The study group was treated with Docetaxel chemotherapy combined with LMWH.The control group was treated with Docetaxel monotherapy until disease progression or adverse reactions became intolerable.The therapeutic effect,changes of coagulation function and adverse reactions were compared between the two groups.Results There was no significant difference in the objective remission rate between the two groups after 2 cycles of treatment(P>0.05).After treatment,the disease control rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the D-dimer and fibrinogen(FIB)in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of deep vein thrombosis in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).There were no significant differences in the adverse reactions between the two groups(P>0.05).Conclusion LMWH combined with Docetaxel for second-line treatment of driver gene-negative advanced NSCLC good short-term efficacy,can improve the short-term disease control rate,improve coagulation function,reduce the occurrence of venous thrombosis.

关 键 词：低分子肝素 多西他赛 非小细胞肺癌 二线化疗 

分 类 号：R734.2[医药卫生—肿瘤]